The Technical Analyst
Vertex Pharmaceuticals [VRTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vertex Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.12% $400.37
America/New_York / 24 apr 2024 @ 11:27
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 103 419 mill |
| EPS: | 13.88 |
| P/E: | 28.85 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 258.31 mill |
| Avg Daily Volume: | 1.212 mill |
| RATING 2024-04-23 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 28.85 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 4.91x |
| Company: PE 28.85 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$619.89 (54.83%) $219.52 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 392.70 - 407.80 ( +/- 1.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Sachs Bruce I | Buy | 109 | Deferred Stock Units |
| 2024-04-01 | Ambrose Kristen | Sell | 225 | Common Stock |
| 2024-04-02 | Ambrose Kristen | Sell | 240 | Common Stock |
| 2024-02-23 | Wagner Charles F Jr | Sell | 3 309 | Common Stock |
| 2024-02-23 | Tatsis Ourania | Sell | 3 309 | Common Stock |
| INSIDER POWER |
|---|
| 11.73 |
| Last 100 transactions |
| Buy: 259 544 | Sell: 201 703 |
Forecast:
13:07 - $399.24
Live Trading Signals (every 1 min)
Forecast
1: 11:37 - $400.26
Forecast 2: 12:27 - $399.21
Forecast 3: 13:07 - $399.24
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $400.37 (-1.12% ) |
| Volume | 0.241 mill |
| Avg. Vol. | 1.212 mill |
| % of Avg. Vol | 19.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VRTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $421.75 | N/A | Active |
|---|
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-04-23 00:45:00 - Press Release
Vertex And Treefrog Therapeutics Announce Licensing Agreement And Collaboration To Optimize Production Of Vertex's Cell Therapies For Type 1 Diabetes
Vertex obtains an exclusive license to treefrog's c-stemtm manufacturing technology in type 1 diabetes treefrog and vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells boston and bordeaux, france , april 23, 2024 /prnewswire/ -- vertex pharmaceuticals incorporated (nasdaq: vrtx) and treefrog therapeutics today announced that vertex has obtained an exclusive license to treefrog's proprietary cell manufacturing technology, c-stemtm, to optimize production of vertex's cell therapies for type 1 diabetes (t1d). treefrog and vertex will collaborate to scale-up treefrog's process to produce and amplify cells for vertex's t1d therapies.
2024-04-18 08:00:00 - Press Release
Vertex Announces Advancements Of Suzetrigine (vx-548) In Acute And Neuropathic Pain
Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. suzetrigine is an oral selective nav1.8 pain signal inhibitor (formerly known as vx-548). following the positive phase 3 results in acute pain announced in january 2024, the food and drug administration (fda) has granted a rolli.
2024-04-12 17:17:00 - Press Release
Alpine Immune Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Alpine Immune Sciences, Inc. - Alpn
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of alpine immune sciences, inc. (nasdaqgm: alpn) to vertex pharmaceuticals incorporated (nasdaqgs: vrtx). under the terms of the proposed transaction, shareholders of alpine will receive $65.00 in cash for each share of alpine that they own. ksf is seeking to determine whether this consideration and the process t.
2024-04-10 16:01:00 - Press Release
Vertex Enters Into Agreement To Acquire Alpine Immune Sciences
Boston & seattle--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and alpine immune sciences, inc. (nasdaq: alpn), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which vertex will acquire alpine for $65 per share or approximately $4.9 billion in cash. the transaction was unanimously approved by both the vertex and alpine boards of direct.
2024-04-09 16:05:00 - Press Release
Vertex To Announce First Quarter 2024 Financial Results On May 6
Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) will report its first quarter 2024 financial results on monday, may 6, 2024 after the financial markets close. the company will host a conference call and webcast at 4:30 p.m. et. to access the call, please dial (833) 630-2124 (u.s.) or +1 (412) 317-0651 (international) and reference the “vertex pharmaceuticals first quarter 2024 earnings call.” the conference call will be webcast live and a link to the webcast can be a.
Latest News
2024-04-23 09:10:27 - Zacks Investment Research
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
2024-04-23 06:05:00 - The Motley Fool
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings.
2024-04-22 07:16:55 - The Motley Fool
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
Vertex is a leader in cystic fibrosis treatment but also is showing it can succeed in other disease areas. The company recently won approval for a gene-editing treatment for blood disorders.
2024-04-22 05:52:00 - The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
One of these magnificent stocks could be a big winner in a new $4 trillion market. Another is a leader in using AI to automate online processes.
2024-04-20 09:45:00 - The Motley Fool
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.
2024-04-20 06:48:00 - The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.
2024-04-20 06:15:00 - InvestorPlace
3 Biotech Stocks Set to Double by 2028
Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years.
2024-04-19 13:01:21 - Zacks Investment Research
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
2024-04-19 04:30:00 - The Motley Fool
Is Vertex Pharmaceuticals Stock a Millionaire Maker?
Vertex is growing beyond its highly successful cystic fibrosis business and into other areas of healthcare. The added growth opportunities should accelerate its growth rate, which slowed down last year.
2024-04-18 08:30:00 - The Motley Fool
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences' leading candidate looks highly promising.